Scholarlink

Aim <p>We investigated the usefulness of serum CXCL10 levels for predicting prognosis in hepatitis C virus (HCV)-infected patients with compensated and decompensated cirrhosis (cLC and dLC) after direct-acting antiviral (DAA) therapy.</p> Methods <p>This nationwide multicenter study enrolled 212 HCV-associated LC patients, consisting of 113 cLC and 99 dLC patients, receiving DAA therapy, who had preserved serum samples. Serum CXCL10 levels were measured at pretreatment (pre-CXCL10) and posttreatment (12 or 24&#xa0;weeks after the end of treatment: EOT12W or EOT24W) (post-CXCL10). We evaluated the relationship between these levels and liver transplantation (LT)-free overall survival (OS) and clinical outcomes.</p> Results <p>During the observational period (median: 37&#xa0;months), 27 patients developed dLC events and 20 died. The post-CXCL10 levels were significantly higher in dLC than in cLC (<i>P</i> = 0.006) and among patients who died than those who survived (<i>P</i> &lt; 0.001). The cutoff value of serum post-CXCL10 level for discriminating the occurrence of death (345&#xa0;pg/mL) could predict LT-free OS in groups of all, cLC, and dLC patients (<i>P</i> &lt; 0.001, <i>P</i> = 0.007, and <i>P</i> &lt; 0.001, respectively). Multivariate analysis on factors associated with LT-free OS demonstrated that age (HR 1.076; <i>P</i> = 0.013), Child–Pugh score at EOT12W (HR 1.575; <i>P</i> = 0.009), and serum post-CXCL10 level (HR 1.003; <i>P</i> = 0.001) were independent factors.</p> Conclusions <p>The serum post-CXCL10 level was independently related to survival in HCV-associated LC patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Posttreatment serum CXCL10 level stratifies survival in compensated and decompensated cirrhotic patients due to chronic hepatitis C virus infection after direct-acting antiviral therapy

  • 期刊论文

  • 发表日期：

    2025年7月1日

查看全文
  • Takanori Suzuki,
  • Kentaro Matsuura,
  • Yuki Tahata,
  • Hayato Hikita,
  • Ryotaro Sakamori,
  • Norifumi Kawada,
  • Nobuyuki Enomoto,
  • Daiki Miki,
  • Hiroshi Yatsuhashi,
  • Hidekatsu Kuroda,
  • Taro Yamashita,
  • Hitoshi Yoshiji,
  • Masayuki Kurosaki,
  • Seiichi Mawatari,
  • Hisamitsu Miyaaki,
  • Yasuhiro Asahina,
  • Yoichi Hiasa,
  • Satoshi Mochida,
  • Yasunari Nakamoto,
  • Taro Takami,
  • Takahiro Kodama,
  • Tomohide Tatsumi,
  • Tetsuo Takehara

摘要

Aim

We investigated the usefulness of serum CXCL10 levels for predicting prognosis in hepatitis C virus (HCV)-infected patients with compensated and decompensated cirrhosis (cLC and dLC) after direct-acting antiviral (DAA) therapy.

Methods

This nationwide multicenter study enrolled 212 HCV-associated LC patients, consisting of 113 cLC and 99 dLC patients, receiving DAA therapy, who had preserved serum samples. Serum CXCL10 levels were measured at pretreatment (pre-CXCL10) and posttreatment (12 or 24 weeks after the end of treatment: EOT12W or EOT24W) (post-CXCL10). We evaluated the relationship between these levels and liver transplantation (LT)-free overall survival (OS) and clinical outcomes.

Results

During the observational period (median: 37 months), 27 patients developed dLC events and 20 died. The post-CXCL10 levels were significantly higher in dLC than in cLC (P = 0.006) and among patients who died than those who survived (P < 0.001). The cutoff value of serum post-CXCL10 level for discriminating the occurrence of death (345 pg/mL) could predict LT-free OS in groups of all, cLC, and dLC patients (P < 0.001, P = 0.007, and P < 0.001, respectively). Multivariate analysis on factors associated with LT-free OS demonstrated that age (HR 1.076; P = 0.013), Child–Pugh score at EOT12W (HR 1.575; P = 0.009), and serum post-CXCL10 level (HR 1.003; P = 0.001) were independent factors.

Conclusions

The serum post-CXCL10 level was independently related to survival in HCV-associated LC patients.